Amanda Hull

Amanda Hull

Auto-generated profile, based on publicly available information

Amanda Hull

Department of Obstetrics, Gynecology and Women’s Health, University of Missouri School of Medicine, Columbia, MO, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKylie Black
Kylie Black
OPOm Pandey
Om Pandey
BMBrent McPherson
Brent McPherson
JHJohn Hainline
John Hainline
SBShawyon Baygani
Shawyon Baygani
AKAnna Kalinovsky
Anna Kalinovsky
The cerebellum is the only folded cortical structure present in both rodents and humans, allowing mechanistic studies of gyrification across species. In mice, the extent of anterior vermis folding and the shapes of white matter exhibit sex-dependent differences. We trained a deep convolutional neural network to predict biological sex from midline cerebellar MRI images, showing that human cerebellar midvermis contains sex-dependent anatomical features. Our comparative cross-species analysis shows that in both species, sex and anterior vermis folding patterns are not enough to predict an individual’s behavior because the variability in performance between individuals is far greater than the differences between conditions. Finally, utilizing constitutive cannabinoid receptor 1 (CB1) knockout (KO) mice, we identify developmental cannabinoid signaling as a novel molecular mechanism limiting secondary fissure formation. Teaser: Males and females display differences in the architecture of cerebellar folding shaped by cannabinoid signaling during development.

12 October 2026 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
KDKrystina Dunston
Krystina Dunston
KKKeun Cheon Kim
Keun Cheon Kim
SNShamsun Nahar
Shamsun Nahar
JYJUNG-YOON YOO
JUNG-YOON YOO
AHAmanda Hull
Amanda Hull
Tai-hoon KimTai-hoon Kim
Tai-hoon Kim
Introduction: Endometrial Cancer (EC) is the most prevalent gynecologic malignancy, and its incidence continues to rise globally. PTEN mutations occur frequently in EC and lead to aberrant activation of the PI3K/AKT pathway, driving uncontrolled cellular proliferation and survival. In murine models, uterine-specific deletion of Pten results in rapid EC development. Emerging evidence implicates Histone Deacetylases (HDACs) as key epigenetic regulators of tumor progression, yet the specific role of HDAC3 in EC remains poorly defined. Methods: We generated uterine-specific Pten and Hdac3 double-knockout mice (Pgrcre/+Hdac3f/fPtenf/f; Hdac3d/dPtend/d) to investigate the functional and therapeutic relevance of HDAC3. Histopathologic analysis was performed to examine the effect of Hdac3 ablation on EC with Pten deficiency compared with Pten single-knockout mice (Pgrcre/+Ptenf/f; Ptend/d) at 1 and 2 months of age. To evaluate the effect of the HDAC3 inhibitor (RGFP966), 6-week-old Ptend/d (Stage Ⅰ EC) mice were treated with vehicle or RGFP966 (10 mg/kg) twice per week for 5 weeks via intraperitoneal injection. Results: Histopathological analysis revealed marked regression of EC in Hdac3d/dPtend/d mice compared to Ptend/d controls to investigate the functional and therapeutic relevance of HDAC3. Pharmacologic inhibition of HDAC3 using the selective inhibitor RGFP966 in Ptend/d mice significantly reduced tumor burden and metastatic dissemination compared to vehicle treatment. Mechanistically, HDAC3 inhibition suppressed tumor cell proliferation and enhanced apoptosis, concomitant with reduced phosphorylation of ERK1/2 and AKT levels. Discussion: While our findings demonstrate significant antitumor effects of HDAC3 inhibition in PTEN-deficient endometrial cancer, further studies are needed to define the downstream molecular pathways responsible for these effects. Conclusion: Collectively, these findings establish HDAC3 as a critical epigenetic driver of endometrial tumorigenesis and support selective HDAC3 inhibition as a promising therapeutic strategy for PTEN-deficient EC.

12 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SKSooah Ko
Sooah Ko
MDMaya Demirchian
Maya Demirchian
EMEdgar Andres Diaz Miranda
Edgar Andres Diaz Miranda
CGCarlye Goldenberg
Carlye Goldenberg
KKKavita Krell
Kavita Krell
LLLei Lei
Lei Lei
Objective: The purpose of this study is to determine how family history of cancer, genetic mutations, presenting symptoms, and comorbidity burden collectively influence cancer outcomes in patients with epithelial ovarian cancer. Methods: A retrospective analysis was conducted on all patients with epithelial ovarian cancer treated at the University of Missouri and Ellis Fischel Cancer Center between 2008 and 2024. Patient charts were reviewed for histological subtypes, stage of cancer, status of metastasis, CA-125 values, presenting symptoms, comorbidities, family history of cancer, genetic mutations, and survival outcome. Cox regression and association analyses were performed. Results: In this cohort of patients, comorbidities and genetic mutations did not influence ovarian cancer survival. While histological subtypes, CA-125 levels, and cancer stage remained strongly associated with survival. Significant associations were observed between certain presenting symptoms and cancer histological subtype, a family history of breast cancer, stage of cancer at diagnosis, the status of metastasis, and CA-125 levels. Conclusion: Comorbidities and genetic mutations were not significantly associated with ovarian cancer survival. Presenting symptoms were associated with several clinical and pathological variables linked to ovarian cancer diagnosis.